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ate changes in categorical and continuous variables, respectively.
RESULTS: Total of 102 patients who were followed up for 3
months are included in this analysis. Of which, 43.1% were
male, mean age was 38.5  12.6 years old, and mean time since
diagnosis was 8.9  8.4 years. The ﬁrst reasons for initiating
RLAI were insufﬁcient response to previous medication (43.1%)
and need for maintenance (24.5%). At 3-months, 98% of
patients were still on RLAI treatment. Comparing the ﬁrst
3-month treatment of RLAI to the 3-month period prior to the
initiation of RLAI for the 102 patients, signiﬁcant decreases were
observed in the proportion of patients hospitalized (26.5% vs.
2.9%, p < 0.001) and the mean number of days in hospital (10.2
days vs. 1.3 days, p < 0.001). By 3-months, there were signiﬁcant
improvements in disease severity and patient functioning; the
average CGI-S score signiﬁcantly decreased from 3.74 at baseline
to 3.33 at 3 months (p < 0.001) and the mean GAF score
signiﬁcantly increased from 51.5 at baseline to 56.0 at 3 months
(p < 0.001). CONCLUSIONS: Based on the 3-month interim
results, treatment with RLAI was associated with reductions in
hospitalizations and improvements in disease severity and patient
functioning in Russian patients with schizophrenia.
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OBJECTIVES: Atypical antipsychotics are widely used in the
pharmacologic management of schizophrenia. A meta-analysis of
oral atypical antipsychotics was conducted to assess the relative
effectiveness of a newly introduced agent, paliperidone extended-
release (ER). METHODS: Randomized placebo-controlled
studies of risperidone, olanzapine, quetiapine and aripiprazole
were identiﬁed via a database search (MEDLINE, Embase, the
Cochrane Library, PsycInfo and the Cumulative Index to Nursing
& Allied Health Literature). Baseline demographic, efﬁcacy and
safety data were extracted and combined in the meta-analysis
using the DerSimonian and Laird approach [1]. Random effects
meta-regression1 was used to assess potential confounding by
patient mean age, gender ratio and duration of therapy on vari-
ability in efﬁcacy and safety. RESULTS: Atypical antipsychotics
as a group had lower odds of withdrawal for any reason than
placebo treatment (OR 0.52, 95%CI 0.46, 0.58), with paliperi-
done ER having lower odds than the antipsychotic class as a
whole (OR 0.43, 95%CI 0.34, 0.53). Odds of withdrawal due to
adverse events were lower with paliperidone ER (OR 0.88,
95%CI 0.71, 1.15) than with risperidone (OR 2.09, 95%CI
0.80, 5.41) and with the atypical antipsychotics as a class (OR
1.02, 95%CI 0.83, 1.25). Paliperidone ER was associated with a
lower odds of somnolence (OR 1.33, 95%CI 0.92, 1.94) than the
atypical class (OR 1.70, 95%CI 1.39, 2.09) and a lower odds of
weight gain (OR 1.75, 95%CI 1.29, 2.37) than all of the atypical
antipsychotics, including risperidone (OR 3.08, 95%CI 1.53,
6.20). The predominant factor in the observed variability in
efﬁcacy was the speciﬁc antipsychotic, rather than patient-related
factors or duration of therapy. CONCLUSIONS: Within the
spectrum of efﬁcacy and safety of the class, Paliperidone ER
demonstrates a unique efﬁcacy and tolerability proﬁle. Owing to
the heterogeneity within the class, information on individual
beneﬁt/risk proﬁles of atypical antipsychotics is necessary for
selecting a speciﬁc treatment for each patient. [1] DerSimonian
R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
1986;7:177–88.
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OBJECTIVES: Serotonin is critical for maintaining platelet hae-
mostatic function such as aggregation. SSRI-induced upper
gastrointestinal hemorrhage (UGIH) may occur through SSRI-
induced inhibition of serotonin reuptake by platelets, leading to
depletion of serotonin after several weeks of antidepressant (i.e.
SSRI) treatment. The risk of SSRI-induced-UGIH has not been
documented in a U.S. managed care population. The purpose of
this study was to compare the incremental likelihood of UGIH
events with use of SSRIs and in combination with NSAIDs in a
managed care population. METHODS: A retrospective study
was designed using data from a large managed care claims data-
base. Subjects were identiﬁed anytime between October 1, 2005
to September 30, 2006 (index-period) and classiﬁed into SSRI-
users, NSAID-users or SSRI-NSAID concomitant users. Each
subject was matched to a control (non-SSRI/NSAID-user) based
on their index date. All subjects were treatment naïve 12 months
prior to their pre-index period and followed for 12 months post
index date to determine the risk of any UGIH event based on
ICD-9-CM code. RESULTS: A total of 87,054, 275,476, 27,696,
and 386,248 subjects were identiﬁed as SSRI-users, NSAID-
users, concomitant-users and controls at index-period. The
control group was signiﬁcantly (p < 0.001) younger than the drug
cohorts (31vs. 42years), lower (p < 0.001) proportions of females
(47% vs. 57%), and lower (p < 0.001) burden of comorbid
illness as measured by Charlson Comorbidity Index (0.15 vs.
0.50). Compared to the controls, concomitant-users had 1.0%
(OR = 3.32; 95%CI = 2.90–3.79), SSRI-users had 0.8% (RR =
2.59; 95%CI = 2.36–2.86), and NSAID-users had 0.5% (RR =
1.83; 95%CI = 1.69–1.97) cases with a diagnoses of UGIH.
CONCLUSIONS: Current SSRIs that are recommended as ﬁrst
line therapy for depression is associated with a risk of UGIH
within ﬁrst 12-months either alone or in combination with
NSAIDs. Future research needs to estimate the economic burden
of such bleeding events to managed care.
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OBJECTIVES: To determine the epidemiological, clinical, and
economic burden of bipolar disorder (BD) in Europe.
METHODS: A systematic review of publications from the last 10
years relating to the burden of bipolar disorder was conducted,
including studies on epidemiology, patient-related issues, and
costs. RESULTS: Data from the UK, Germany, and Italy indi-
cated a prevalence of bipolar disorder of ~1%, and a misdiag-
nosis rate of 70% from Spain. In one study, up to 75% of
patients had at least one DSM-IV comorbidity, commonly
anxiety disorders and substance/alcohol abuse. Attempted
suicide rates varied between 21–54%, with 18% mortality in the
UK. The chronicity of bipolar disorder exerted a profound and
debilitating effect on the patient. Only 30% of German patients
were employed full time at a level matching their qualiﬁcations.
In Italy, 63–67% of patients were unemployed and in Germany,
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72% received disability payments. In the UK, the annual costs of
unemployment and suicide were £1510 million and £179
million, respectively. The estimated UK national cost of bipolar
disorder was €4.59 billion, with hospitalization during acute
episodes representing the largest component. CONCLUSIONS:
Bipolar disorder is a major and underestimated health problem in
Europe. A number of issues impact on the burden of the disease,
such as comorbidities, suicide, early death, unemployment or
underemployment. Direct costs of bipolar disorder are mainly
associated with hospitalization during acute episodes. Indirect
costs are a major contributor to the disease burden but are not
always recognized in research studies. Supported by funding
from AstraZeneca Pharmaceuticals LP.
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OBJECTIVES: While pharmacological hepatic interaction
mechanisms for antipsychotics are largely known, there is little
research so far on the prevalence of potential interactions with
other substances. The objective of the present study is to estimate
the annual prevalence of potential pharmacokinetic drug-drug
interactions (DDIs) between antipsychotic and non-antipsychotic
therapies in patients with schizophrenia. METHODS: A retro-
spective analysis of drug prescriptions for patients treated for
schizophrenia (ICD-10 codes F20–F29) was performed using the
German IMS Disease Analyzer data for psychiatrists for 2007.
These data originate from electronic medical records from a
representative panel of German psychiatrists, and include drug
prescriptions and medical diagnoses. Potential antipsychotic
drug-drug interactions based on cytochrome P450 metabolism
(1A2, 2D6, 3A4, and 3A pathways) for antipsychotics and cor-
responding interacting drugs (pathway inducers and inhibitors)
were identiﬁed based on literature and drug information
resources. A potential DDI was identiﬁed when combinations
known to interact had 20 or more days of overlap, determined by
prescription dates, dosing information and pack size. Incidence
of overlap was calculated by antipsychotic, metabolic pathway
and interaction mechanism. RESULTS: A total of 5449 patients
received an atypical antipsychotic. The most frequent interaction
mechanisms were inhibition of CYP2D6 and of CYP3A4:
between 38% and 45% of the patients treated with atypicals had
a 20 day-overlap with inhibitors of CYP2D6, and 17% to 26%
with CYP3A4-Inhibitors. Potential interactions were most com-
monly associated with antidepressants. CONCLUSIONS: The
risk of potential DDI in schizophrenia patients treated with
antipsychotics in Germany is common, mainly due to concomi-
tant prescription of antipsychotics and antidepressants. The
reported estimates are based on real world data for psychiatrists
in Germany, and are conservative, since drugs prescribed by
other physicians or bought over the counter could not be taken
into account.
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OBJECTIVES: In 2002, the National Institute for Health and
Clinical Excellence (NICE) highlighted extrapyramidal symp-
toms (EPS), sexual dysfunction, sedation, and weight gain, as the
outcomes considered by patients taking atypical antipsychotics
to be the most troublesome. This research was designed to
compare the tolerability of the new extended release quetiapine
to the existing quetiapine immediate release formulation on these
outcomes in addition to orthostatic hypotension, which could be
a signiﬁcant cause of morbidity. METHODS: Systematic review
of CENTRAL, BIOSIS, EMBASE and MEDLINE for randomised
controlled trials (RCTs) in patients with acute bipolar disorder
treated with quetiapine was conducted in May 2008. Meta-
analyses of quetiapine vs placebo used a random effects model.
The results from the individual meta-analyses formed the basis of
an adjusted indirect comparison of the two quetiapine formula-
tions using placebo as a common comparator. Summary effect
estimate for each outcome was calculated as relative risk (RR)
with 95% conﬁdence interval (95% CI) where RR < 1 favoured
extended release and RR > 1 favoured immediate release.
RESULTS: Of the 331 papers initially identiﬁed in the literature
search, 5 RCTs compared quetiapine with placebo with a
common daily dose of 300mg (4 RCTs immediate release and 1
RCT extended release). Adjusted indirect comparison identiﬁed
no signiﬁcant differences between the two formulations of que-
tiapine in the outcomes assessed. Individual results were as
follows: EPS RR0.34 (95% CI: 0.04 to 12.07); orthostatic
hypotension RR1.81 (95% CI: 0.19 to 57.84); prolactin RR1.92
(95%CI: 0.11 to 123.24); sedation RR1.09 (95%CI: 0.51 to
6.29); weight gain RR0.26 (95% CI: 0.05 to 6.86). CONCLU-
SIONS: This adjusted indirect comparison of ﬁve placebo-
controlled clinical trials suggests that the tolerability proﬁle of
extended release quetiapine is consistent with that of the imme-
diate release formulation. Further research will need to be con-
ducted to determine if these results are replicated in real-life
clinical practice.
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OBJECTIVES: To compare the tolerability proﬁles of atypical
antipsychotics assessed in randomised controlled trials (RCTs).
METHODS: Systematic review of BIOSIS, CENTRAL,
EMBASE, MEDLINE, PsycINFO for RCTs comparing two or
more atypical antipsychotics (aripiprazole—ARI, olanzapine—
OLZ, quetiapine—QTP, risperidone—RSD, ziprasidone—ZPD).
Searching was restricted to English-language publications and
was completed in December 2007. Data were extracted on the
following outcomes: anxiety or depression, bodily anxiety or
restlessness, dizziness or nausea, extrapyramidal symptoms
(EPS), sexual dysfunction, stiffness or tremor, tiredness or weak-
ness, weight gain. Data were recalculated if not presented in an
intention-to-treat format. Mixed treatment comparisons were
conducted by Bayesian Markov Chain Monte Carlo simulation
using uninformed priors. Summary effect estimates (Odds Ratios
[OR], 95% credible intervals [95%CrI]) were calculated com-
pared to RSD. RESULTS: Of the 2963 papers identiﬁed in the
literature search, 50 were found to provide data on 48 RCTs
comparing two or more atypical antipsychotics. The results pre-
sented a wide spectrum of tolerability among the atypical antip-
sychotics with no single treatment being identiﬁed as consistently
better tolerated than all other. The outcomes that could be con-
sidered statistically signiﬁcant at the 5% level were: decrease in
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